The American Diabetes Association and Xeris Pharmaceuticals Announce National Collaboration to Provide Life-Saving Hypoglycemia Education and Awareness

Core Viewpoint - The American Diabetes Association (ADA) and Xeris Pharmaceuticals have formed a multi-year strategic partnership to promote the importance of glucagon prescriptions for individuals with diabetes on blood glucose-lowering medications, particularly those at risk of severe hypoglycemia [1][2][3] Group 1: Partnership Objectives - The partnership aims to increase awareness and education regarding the necessity of having glucagon, preferably in a ready-to-use formulation, for individuals with diabetes treated with insulin or insulin secretagogues [1][2] - The ADA and Xeris will develop educational materials and training resources for healthcare professionals and individuals living with diabetes, alongside a national awareness campaign [2] Group 2: Health Statistics and Risks - It is estimated that up to 46% of individuals with type 1 diabetes and 21% of those with type 2 diabetes using insulin experience at least one severe hypoglycemia event annually [1] - Severe hypoglycemia is responsible for over 202,000 emergency department visits each year, with approximately 25% of these cases resulting in hospital admissions [1] Group 3: Company Profiles - The ADA is a leading health organization focused on ending diabetes and supporting individuals living with the condition, with 136 million Americans affected by diabetes or prediabetes [4] - Xeris Pharmaceuticals is a biopharmaceutical company that develops innovative products, including Gvoke®, a ready-to-use liquid glucagon for treating severe hypoglycemia [5]